1. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  2. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL (2014) Breast Cancer Res 16(4): R69
    › Primary publication · 24985072 (PubMed) · PMC4095685 (PubMed Central)
  3. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA (2014) Breast Cancer Res 16(4): 406
    › Primary publication · 25103565 (PubMed) · PMC4187324 (PubMed Central)
  4. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  5. Multi-perspective quality control of Illumina exome sequencing data using QC3. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2014) Genomics 103(5-6): 323-8
    › Primary publication · 24703969 (PubMed) · PMC5755963 (PubMed Central)
  6. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
  7. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK (2014) Cancer Res 74(11): 3180-94
    › Primary publication · 24662921 (PubMed) · PMC4096808 (PubMed Central)
  8. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Lehmann BD, Pietenpol JA (2014) J Pathol 232(2): 142-50
    › Primary publication · 24114677 (PubMed) · PMC4090031 (PubMed Central)
  9. Detection of internal exon deletion with exon Del. Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y (2014) BMC Bioinformatics : 332
    › Primary publication · 25322818 (PubMed) · PMC4288651 (PubMed Central)
  10. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Breast Cancer Res 15(1): 201
    › Primary publication · 23339383 (PubMed) · PMC3672825 (PubMed Central)